$5.23+0.02 (+0.38%)
News25/Ratings9
Price$5.23+0.02 (+0.38%)
01:30 PM07:45 PM
News · 26 weeks80+31%
2025-11-022026-04-26
Mix4690d
- Insider18(39%)
- SEC Filings14(30%)
- Other11(24%)
- Analyst2(4%)
- Earnings1(2%)
Latest news
25 items- SECOpus Genetics Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form 144 filed by Opus Genetics Inc.144 - Opus Genetics, Inc. (0001228627) (Subject)
- SECSEC Form EFFECT filed by Opus Genetics Inc.EFFECT - Opus Genetics, Inc. (0001228627) (Filer)
- INSIDERSEC Form 4 filed by Rodgers Richard J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Manuso James S J4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Benton Susan4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Gallagher Cam4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Graves Adrienne L4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Bennett Jean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Ainsworth Sean4 - Opus Genetics, Inc. (0001228627) (Issuer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECAmendment: SEC Form S-3/A filed by Opus Genetics Inc.S-3/A - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual MeetingRESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that three abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026. The presentations will include data across key areas of ophthalmology, including full results from VEGA-3, a Phase 3 study evaluating phentolamine ophthalmic solution 0.75% for presbyopia, and a post-hoc analysis of MIRA-2, a
- SECOpus Genetics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- SECOpus Genetics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Opus Genetics, Inc. (0001228627) (Filer)
- PROpus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment -- Strategic financing to accelerate development of earlier-stage gene therapy programs with three additional programs entering clinical testing over the next year - - Current cash of approximately $100 million now extends cash runway into 2029, through expected completion of OPGx-LCA5 and OPGx-BEST1 pivotal studies, potential approvals, and the prospect to receive priority review vouchers - - Three-month topline results from full Cohort 1 of Phase 1/2 trial with OPGx-BEST1 remain on track for mid-2026 - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (G
- ANALYSTCantor Fitzgerald initiated coverage on Opus Genetics with a new price targetCantor Fitzgerald initiated coverage of Opus Genetics with a rating of Overweight and set a new price target of $15.00
- PROpus Genetics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (NASDAQ:IRD) ("Opus Genetics" or the "Company"), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2026 in the Biotech category. This year's list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World's 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions. "We are honored to be recogniz
- SECSEC Form DEF 14A filed by Opus Genetics Inc.DEF 14A - Opus Genetics, Inc. (0001228627) (Filer)
- INSIDERSEC Form 4 filed by Schachle Joseph K4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Zaremba Rabourn Amy4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Magrath George4 - Opus Genetics, Inc. (0001228627) (Issuer)
- INSIDERSEC Form 4 filed by Jayagopal Ashwath4 - Opus Genetics, Inc. (0001228627) (Issuer)
- ANALYSTOppenheimer initiated coverage on Opus Genetics with a new price targetOppenheimer initiated coverage of Opus Genetics with a rating of Outperform and set a new price target of $10.00